Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with inflammatory bowel disease

被引：0
|
作者：
van Hoeve, K. [1 ]
Dreesen, E. [2 ]
Hoffman, I. [1 ]
Ferrante, M. [3 ]
Vermeire, S. [3 ]
机构：
[1] Univ Hosp Leuven, Dept Paediat Gastroenterol & Hepatol & Nutr, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Lab Therapeut & Diagnost Antibodies, Leuven, Belgium
[3] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P389
引用
收藏
页码：S362 / S363
页数：2
相关论文
共 50 条
  • [1] INFLIXIMAB SERUM LEVELS DURING INDUCTION PREDICT LONG-TERM ENDOSCOPIC REMISSION IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Ferrante, Marc
    Vermeire, Severine
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S968 - S968
  • [2] Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease
    Perdigoto, D.
    Portela, F.
    Ferreira, M.
    Mendes, S.
    Freire, P.
    Ferreira, M.
    Lopes, S.
    Tome, L.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S386 - S386
  • [3] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
    Bodini, G.
    Del Nero, L.
    Giannini, E. G.
    Tolone, S.
    De Bortoli, N.
    Anjali, J.
    Baldissarro, I.
    Savarino, V.
    Savarino, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409
  • [4] Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease
    Bodini, Giorgia
    Giannini, Edoardo G.
    Savarino, Vincenzo
    Del Nero, Lorenzo
    Lo Pumo, Sara
    Brunacci, Matteo
    De Bortoli, Nicola
    Jain, Anjali
    Tolone, Salvatore
    Savarino, Edoardo
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (05) : 452 - 456
  • [5] Infliximab trough levels after induction therapy are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Hoffman, I.
    Dreesen, E.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S183 - S183
  • [6] VEDOLIZUMAB LEVELS DURING INDUCTION ARE ASSOCIATED WITH LONG-TERM CLINICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Yarur, Andres J.
    Bruss, Alexandra
    Berens, Brandon
    Fox, Caroline
    Beniwal-Patel, Poonam M.
    Patel, Amir
    Ungaro, Ryan C.
    Dubinsky, Marla
    Naik, Snehal
    Stein, Daniel J.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S827 - S828
  • [7] Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
    Yarur, A.
    Bruss, A.
    Fox, C.
    Beniwal-Patel, P.
    Patel, A.
    Berens, B.
    Naik, S.
    Stein, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S64 - S65
  • [8] Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
    Orfanoudaki, E.
    Gazouli, M.
    Foteinogiannopoulou, K.
    Theodoraki, E.
    Legaki, E.
    Koutroubakis, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S375 - S376
  • [9] Infliximab trough levels during maintenance are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Hoffman, I.
    Dreesen, E.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S180 - S181
  • [10] Early infliximab trough levels in paediatric IBD patients predict sustained remission
    Bevers, Nanja
    Aliu, Arta
    Wong, Dennis R.
    Winkens, Bjorn
    Vreugdenhil, Anita
    Pierik, Marieke J.
    Derijks, Luc J. J.
    van Rheenen, Patrick F.
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
12345